FMP

FMP

Enter

IDXG - Interpace Biosc...

photo-url-https://images.financialmodelingprep.com/symbol/IDXG.png

Interpace Biosciences, Inc.

IDXG

PNK

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

0.89 USD

-0.03 (-3.37%)

Historical Prices

From:

To:

0.460.50.60.70.80.90.9212:48 PM

About

ceo

Dr. Thomas W. Burnell Ph.D.

sector

Healthcare

industry

Medical - Diagnostics & Research

exchange

PNK

Description

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a geno...

CIK

0001054102

ISIN

US46062X3035

CUSIP

46062X303

Address

Morris Corporate Center 1

Phone

855 776 6419

Country

US

Employee

108

IPO Date

May 20, 1998

Financial Statement

-3M03M6M9M12M15M2023 Q32023 Q42024 Q12024 Q22024 Q3RevenueNet Income

Earnings

-0.4-0.200.20.40.62022 Q42023 Q12023 Q22023 Q32023 Q42024 Q12024 Q22024 Q3EPS Consensus

IDXG Financial Summary

CIK

0001054102

Exchange

PNK

Industry

Medical - Diagnostic...

Sector

Healthcare

CUSIP

46062X303

ISIN

US46062X3035

Country

US

Price

0.89

Beta

0.63

Volume Avg.

18k

Market Cap

3.92M

Shares

-

52-Week

0.52-3.54

DCF

3.12

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

0.81

P/B

-

Website

https://www.interpace.com

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

Latest IDXG News

GlobeNewsWire

Oct 15, 2021

Interpace Biosciences Announces New $7.5 Million Credit Faci...

PARSIPPANY, NJ, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that it, along with its subsidiaries, has entered into a new $7.5 Million revolving credit facility with Comerica Bank (the “Bank”). The facility matures on September 30, 2023 and allows for advances based on 80% of eligible accounts receivable plus an applicable non-formula amount consisting of $2,000,000 of additional availability at close, stepping down $2...

Zacks Investment Research

Aug 10, 2021

Interpace Biosciences, Inc. (IDXG) Reports Q2 Loss, Tops Rev...

Interpace Biosciences, Inc. (IDXG) delivered earnings and revenue surprises of -72.92% and 0.50%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research

Jul 1, 2021

Interpace Biosciences, Inc. (IDXG) Is a Great Choice for "Tr...

Interpace Biosciences, Inc. (IDXG) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

GlobeNewsWire

May 11, 2021

Interpace Biosciences Announces First Quarter 2021 Financial...

PARSIPPANY, NJ, May 11, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fiscal quarter ended March 31, 2021 and provided a business and financial update.

GlobeNewsWire

Apr 19, 2021

Interpace Biosciences Raises Full Year 2021 Revenue Guidance

Parsippany, NJ, April 19, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced an update to its full year 2021 revenue guidance originally provided on March 31, 2021.

GlobeNewsWire

Apr 12, 2021

Interpace Pharma Solutions Announces New Advanced Offering i...

Parsippany, NJ, April 12, 2021 (GLOBE NEWSWIRE) -- Interpace Pharma Solutions, a subsidiary of Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today new capability in advancing RNA biomarker analysis for gene and cell-based therapies.

GlobeNewsWire

Apr 5, 2021

Interpace Biosciences Announces New PLA Code and Medicare Re...

Parsippany, NJ, April 05, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today that Novitas, its Medicare Administrative Contractor, has agreed to recognize the new Proprietary Laboratory Analysis (PLA) code that specifically identifies ThyGeNEXT® as a distinct test from any other test or service. PLA codes are an addition to the current procedural terminology (CPT®) code set approved by the American Medical Association CPT® Editorial ...

GlobeNewsWire

Mar 31, 2021

Interpace Biosciences Announces Full Year and Fourth Quarter...

PARSIPPANY, NJ, March 31, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fiscal quarter ended December 31, 2020 and provided a business and financial update.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep